Results 121 to 130 of about 1,717 (156)

Emerging Antimicrobial Strategies Against Heterogeneous and Vancomycin-Intermediate <i>Staphylococcus aureus</i>. [PDF]

Int J Gen Med
Wang Y, Sun Y, Chen G, Cheng X.
europepmc   +1 more source

The New Path Forward for Prior Authorizations: Navigating Differences in the Accepted Standards of Care, Society Guidelines, and FDA-approved Indications. [PDF]

Open Forum Infect Dis
Desai AN, Rauseo A, Rogan GN, Spec A, Thompson GR.   +4 more
europepmc   +1 more source

Pharmacology of emerging drugs for the treatment of multi-drug resistant tuberculosis. [PDF]

J Clin Tuberc Other Mycobact Dis
Johnson TM, Rivera CG, Lee G, Zeuli JD.
europepmc   +1 more source

Combination Antibiotic Therapy for Orthopedic Infections. [PDF]

Antibiotics (Basel)
Bonnet E, Lourtet-Hascoët J.
europepmc   +1 more source

Unveiling the emergence of community-acquired methicillin-resistant <i>Staphylococcus aureus</i> (CA-MRSA) in Chinese hospitals with remarkable genetic diversity: a multicenter molecular epidemiological investigation. [PDF]

Microbiol Spectr
Tu S, Zhang X, Xu Q, Han W, Cai Y, Liu S, Wang J, Wang H, Chen H.   +8 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Tedizolid: A new oxazolidinone antimicrobial

American Journal of Health-System Pharmacy, 2014
The mechanism of action, pharmacokinetics, pharmacodynamics, and clinical efficacy and safety of an investigational second-generation oxazolidinone are reviewed.Tedizolid is a protein synthesis inhibitor in clinical development for the treatment of gram-positive infections.
Kisgen, Jamie J., Mansour, Hanine, Unger, Nathan R., Childs, Lindsay M   +3 more
openaire   +3 more sources

Long-term use of tedizolid for pulmonary nocardiosis

Journal of Infection and Chemotherapy, 2022
Nocardiosis usually occurs in immunocompromised patients and causes infections in various organs, including the lungs, skin, and organs of the central nervous system. Herein, we report the case of a patient with minimal change nephrotic syndrome who had been on immunosuppressive drugs and developed pulmonary nocardiosis due to Nocardia nova complex and
Yuri Chomei, Sho Nishimura, Kentaro Iwata   +2 more
openaire   +2 more sources

A closer inspection of tedizolid

The Lancet Infectious Diseases, 2015
I read the Article by Gregory Moran and colleagues, who used intention to treat (ITT) analysis of a noninferiority trial, with great interest. ITT is widely accepted as the appropriate analysis for randomised controlled trials. However, this recognition is based on assumptions of trial design. Superiority trials (ie, the attempt to prove treatment A is
openaire   +4 more sources